KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Gains from Investment Securities: 2009-2025

Historic Gains from Investment Securities for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Sep 2025 value amounting to $479.6 million.

  • Vertex Pharmaceuticals' Gains from Investment Securities rose 159766.67% to $479.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 46.01%. This contributed to the annual value of $1.1 billion for FY2024, which is 35.49% down from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Gains from Investment Securities stood at $479.6 million, which was up 12.27% from $427.2 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Gains from Investment Securities ranged from a high of $758.2 million in Q4 2023 and a low of -$49.2 million during Q2 2022.
  • Over the past 3 years, Vertex Pharmaceuticals' median Gains from Investment Securities value was $233.5 million (recorded in 2024), while the average stood at $237.2 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Gains from Investment Securities slumped by 3,175.00% in 2022 and then skyrocketed by 159,766.67% in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Gains from Investment Securities (Quarterly) stood at $94.8 million in 2021, then skyrocketed by 129.64% to $217.7 million in 2022, then skyrocketed by 248.28% to $758.2 million in 2023, then slumped by 64.15% to $271.8 million in 2024, then surged by 159,766.67% to $479.6 million in 2025.
  • Its Gains from Investment Securities stands at $479.6 million for Q3 2025, versus $427.2 million for Q2 2025 and $270.5 million for Q1 2025.